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An Investigation into the Prevalence of Vancomycin-resistant
Enterococci within an Irish Hospital
Dylan Casey
Department of Biological Sciences, Munster Technical University, Bishopstown, Cork, Ireland.
Department of Microbiology, Mercy University Hospital, Grenville Place, Cork, Ireland.

ABSTRACT
Vancomycin-resistant enterococci (VRE) are well-recognised nosocomial pathogens that pose a
significant threat to public health. Associated with poorer clinical outcomes than their vancomycinsensitive counterparts, the prevalence of VRE in Ireland has increased in recent times, with the
European Antimicrobial Resistance Surveillance Network reporting that out of 29 countries, Ireland
demonstrated the highest rates of vancomycin resistance among invasive Enterococcus faecium isolates
between 2011 and 2014 (2011; 34.9%, 2012; 44.0%, 2013; 42.7%, 2014; 45.1%). Herein, we investigate
VRE prevalence in the Mercy University Hospital (MUH) – an acute care hospital in southern Ireland.
A total of 21 first-time VRE infections were identified over a 40 day period between January and March
2021, representing a prevalence of 24.7%. In addition, one vancomycin-sensitive linezolid-resistant
strain was isolated from an Intensive Care patient, and environmental analysis revealed the presence of
an extensive VRE reservoir, with isolates identified on a keyboard, bedside desk, and electricity bar of
a primary observation unit. We also highlight the actions taken – including staff training and surface
decontamination – to curb transmission of the pathogen and prevent a full-scale VRE outbreak
developing within the hospital.
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INTRODUCTION
The bacterial genus Enterococcus, of the phylum Firmicutes, are a ubiquitous cohort of Gram-positive
bacteria that present a formidable challenge to public health (García-Solache & Rice, 2019). While they
normally reside in the gastrointestinal tract of humans and other mammals, enterococci have been
isolated from many extraenteric habitats, including beach sand, terrestrial vegetation, and bodies of
water (Byappanahalli et al., 2012). Indeed, Neely & Maley, (2000) have documented the survival of
Enterococcus faecium, Enterococcus faecalis, Enterococcus gallinarum, and Enterococcus
casseliflavus on both polyester and polyethylene surfaces, such as may be used in hospital privacy
curtains and splash aprons, respectively, for longer than 90 days. Isolates of E. faecium have also been
shown to remain viable on a 60% cotton-40% polyester blend, as would be encountered on lab coats
and scrub suits, for this same time period (Neely & Maley, 2000).
Enterococcal persistence in these environments is of particular concern when the ability of the organism
to cause disease is considered; although most species are commensal bacteria, some are implicated in
urinary tract infections, wound infections, and infective endocarditis, among others (Byappanahalli et
al., 2012; Iaria et al., 2005; Rajkumari et al., 2014; Selleck et al., 2019). Some species, most often E.
faecalis and E. faecium, are capable of causing severe bacteraemia – a condition characterised by high
mortality rates (up to 40%) in critically-ill patients (Alqarni et al., 2018; Leibovici, 1995; Rosselli Del

Turco et al., 2020). Given that the pathogen is intrinsically resistant to many first-line antibiotics (e.g.
-lactams and aminoglycosides), treatment of enterococcal illness can be complex, often requiring the
use of sophisticated, novel antimicrobials (Kristich et al., 2014). Vancomycin, a glycopeptide antibiotic
that was discovered in the 1950s, initially provided an alternative means of treating multidrug-resistant
strains. This success was short-lived however, and vancomycin-resistant enterococci (VRE) were
isolated from several patients with end-stage renal failure in 1988 – heralding the birth of a new era in
the war against the pathogen (Griffith, 1984; Uttley et al., 1988).
Since then, VRE have become a well-established source of nosocomial infection, posing a significant
threat to patients in high-dependency settings such as transplantation units, oncology wards, and
intensive-care units (ICUs) (Austin et al., 1999; Uttley et al., 1988). Within hospitals, VRE carriage is
strongly correlated with an increased average length of stay (LOS) and a notably higher cost of
hospitalisation (Jung et al., 2014). For these reasons, prevention of nosocomial VRE infection is of
paramount importance and due consideration must be given to implement measures that are known to
curb transmission of the pathogen. Nonetheless, VRE outbreaks remain a problem in healthcaresettings, with Weterings et al., (2021) recently describing a hospital-wide vancomycin-resistant E.
faecium (VREfm) outbreak in The Netherlands that took over 2 years to control. In addition, a 2014
report by the European Antimicrobial Resistance Surveillance Network (EARS-Net) showed that of the
29 EU countries from which data was provided, only 4 countries – Iceland, Estonia, Malta, and Finland
– reported a complete absence of vancomycin resistance among invasive E. faecium isolates. Perhaps
of more concern, however, was that Ireland, at 45.1%, recorded the highest percentage of invasive
VREfm isolates out of all 29 countries. Furthermore, a longitudinal analysis by Mendes et al. (2016)
showed that between 2001 and 2014, Ireland reported the 3rd highest percentage (5%) of E. faecium
isolates among blood culture specimens, with only Turkey (5.6%) and Germany (6.1%) reporting a
higher mean figure for the 14 year period.
While much research regarding VRE prevalence has been conducted elsewhere in Europe, hospital
surveillance of the pathogen is not as prominent in Ireland particularly outside of Dublin. Recent studies
by Ryan et al. (2015) and Mcdermott et al (2018) have investigated VRE trends in Irish hospitals, but
these are limited to specific sample types (blood cultures) and wards (ICUs), respectively. Thus, the
current study seeks to provide a comprehensive analysis that is not confined to the aforementioned
factors, thereby generating an accurate picture – or snapshot – of VRE prevalence over a defined time
period. In addition to analysing clinical samples, environmental sampling was conducted in order to
elucidate the modes of transmission responsible for VRE infection and provide a means for limiting
VRE persistence and spread.

MATERIALS AND METHODS
Clinical analysis
Sample cohort
Between the 28th of January 2021 and the 9th of March 2021 a VRE prevalence study was conducted in
the Mercy University Hospital (MUH) (a 330-bed acute general hospital located in the inner city of
Cork, Ireland). The sample cohort included those from patients in which a VRE screen was specifically
requested (i.e. rectal swabs), in addition to microbiological investigations whereby the identification of
an enterococcus warranted a VRE investigation to be subsequently conducted. A total of 98 clinical
samples, comprising 18 different sample types, were submitted for analysis (abscess swabs, blood
cultures, bone fragments, drain fluids, ear swabs, epigastric fluids, faecal samples, finger swabs, groin
swabs, leg swabs, lesion swabs, penile swabs, rectal swabs, stoma swabs, ulcer swabs, urine samples,
vaginal swabs, and wound swabs). While most samples (n=78) were obtained from patients within the
MUH, some samples were from patients in other Cork-based medical practices, namely South Infirmary
Victoria University Hospital (SIVUH) (n=18), Hollyhill Medical Centre (n=1), and Shandon Medical

Centre (n=1). Duplicate positives (i.e. more than one positive result from the same patient) were
excluded from prevalence data, but were included in data relating to sample type (as some VRE carriers
submitted more than one positive sample type during the study, this data was included). Similarly,
where duplicate positives were obtained, antimicrobial susceptibility testing (AST) was only performed
on the initial positive sample in line with the hospital policy regarding the frequency of testing of VRE
isolates. Given that a large proportion of samples arose from repeated VRE screening of patients,
duplicate negatives were included in prevalence data. Patient names and identifiers were omitted in
accordance with the ethical approval granted for this study.
VRE screening samples (rectal swabs)
Rectal swabs were directly plated onto chromogenic selective agar (chromID VRE Agar, bioMérieux
SA, Marcy-l’Étoile, France) and incubated aerobically at 36C for 48 hours. Plates were analysed twice
during this time period (at 24-hour intervals), and presumptive positive VRE were confirmed by
identification testing (GP card) and AST analysis (AST-P662 card) performed on the VITEK 2 Compact
analyser (bioMérieux SA, Marcy-l’Étoile, France). Plates with no visible growth after 48 hrs. incubation
were reported as negative and subsequently discarded. A purity check plate analysis, performed on
Columbia Blood Agar (Columbia agar + 5% sheep blood, bioMérieux SA, Marcy-l’Étoile, France), was
conducted for all VITEK samples. Purity check plates were incubated for 24 hours in the presence of
5% CO2 and examined for pure growth to ensure the absence of contaminating organisms that could
interfere with VITEK analysis.
Non-VRE screening samples
For non-VRE screening samples (i.e. those in which during the course of another microbiological
investigation an enterococcus was isolated), the protocol followed was similar to rectal swabs in that
suspect enterococci were cultured onto chromogenic agar and incubated under the same conditions.
Presumptive positive VRE colonies were then confirmed via identification and AST analysis on the
VITEK 2 Compact analyser. In addition, one vancomycin-sensitive isolate, obtained from an ICU
patient, also underwent VITEK analysis. For blood culture specimens specifically, initial VRE
identification was not performed on chromogenic agar, but rather on the BioFire FilmArray analyser
(BioFire Diagnostics, LLC, Utah, USA) (as per the hospital policy regarding the investigation of
positive blood culture specimens). VITEK confirmatory testing (identification and AST analysis) was
conducted on these specimens thereafter.
Confirmation of results
For all sample types, a positive case of VRE was defined as the presence of characteristic VRE growth
on chromogenic agar (or a positive FilmArray result in the case of blood cultures), in addition to a
positive confirmatory result on the VITEK 2 Compact analyser. The genetic mechanism of vancomycinresistance was determined for VRE isolates by using the VITEK 2 Compact’s inbuilt susceptibilitybased prediction of van genotypes, as described by Abele-Horn et al., (2006). For linezolid-resistant
isolates, confirmatory PCR testing was conducted in the National MRSA Reference Laboratory
(NMRSARL, St. James’s Hospital, Dublin, Ireland).
Environmental analysis
Environmental sampling was conducted on the 4th of March 2021 in a 5-bedded observation room within
the male surgical ward from which an atypically high number of clinical VRE isolates originated (Table
1). Based upon the layout of the room, which was compact with uneven surfaces, swabbing was deemed
the most appropriate sampling method (in line with the recommendations of Rawlinson et al., (2019)).
A total of 30 swabs from three distinct areas of the room were sampled namely the front desk area
(n=12), the patient bedding area (n=11), and the toilet area (n=7). All samples were collected using the
Copan Liquid Amies Elution Swab (eSwab) Collection and Transport System (Copan Diagnostics
Inc., Murrieta, CA, USA). To standardise the swabbing process, a uniform technique, as described by

Margas et al., (2013), was employed on all surfaces. All samples were refrigerated at 3C for 24 hours,
and after this period were streaked onto chromID VRE Agar and incubated at 36C for 48 hours. As
for clinical samples, plates were checked for evidence of growth twice during this time period (at 24hour intervals), and those with no visible growth after 48 hours were reported as negative and
subsequently discarded. For plates with mixed (i.e. presumptive VRE colonies in addition to at least
one unrelated colony) or sparse growth (i.e.  3 presumptive VRE colonies) after primary culture,
isolated presumptive VRE colonies were subcultured onto fresh VRE plates to eliminate contaminating
organisms and enhance VRE retrieval. Presumptive VRE colonies were then confirmed via
identification (GP card) and AST analysis (AST-P662 card) on the VITEK 2 Compact analyser. As for
clinical samples, a purity check plate analysis was conducted for all environmental samples that
underwent VITEK analysis. The gold-standard colony-forming unit count (CFU count) method was
used to estimate microbial abundance in primary cultures, with the degree of growth denoted by -, +,
++, +++, and ++++ (where ‘-‘ = no growth; ‘+’ = 1-100 CFU; ‘++’ = 101-200 CFU; ‘+++’ = 201-300
CFU; ‘++++’ = too numerous to count (TNTC) (>300 CFU)) (Hazan et al., 2012).
Infection prevention and control
The infection control measures that were implemented in response to this studies’ findings were based
on the guidelines set out by the Hospital Infection Controls Practice Advisory Committee (HICPAC)
as regards preventing the spread of vancomycin-resistance in the hospital setting (CDC, 1995).
Statistical analysis
Prevalence was calculated by using the following formula:
prevalence (%) =

𝑛𝑜. 𝑜𝑓 𝑓𝑖𝑟𝑠𝑡−𝑡𝑖𝑚𝑒 𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛𝑠
𝑛𝑜. 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑎𝑛𝑎𝑙𝑦𝑠𝑒𝑑 (𝑒.𝑑.𝑝.)

x

100
1

, where e.d.p. = excluding duplicate positives.

Confidence intervals (CI) were calculated by using the binomial proportion confidence interval formula:
𝑝̂ (1 − 𝑝̂ )⁄
𝑛 , where 𝑝̂ is the sample proportion, 𝑧 is the standard normal value for the CI
(1.96 for a 95% CI), and 𝑛 is the sample size.
𝑝̂ ± 𝑧 ∗ √

Ethical approval
Ethical approval for this study was granted by the Clinical Research Ethics Committee, Cork (Review
reference number ECM 4 (q)).

RESULTS AND DISCUSSION
Clinical analysis
During the 40 day period between the 28th of January 2021 and the 9th of March 2021, a total of 98 clinical
samples were investigated, with 34 positive for VRE (n=21 first-time infections and n=13 duplicate
positives) (Table 1). Excluding duplicates (i.e. non-first-time infections), the prevalence of VRE in this
study was 24.7% (21 out of 85 specimens) (95% confidence interval (CI): 15.5%-33.9%). The
remaining 64 samples were either negative for bacterial growth or contained unrelated organisms or
vancomycin-sensitive enterococci. These data reveal a pronounced VRE reservoir within the patient
population and our findings are in line with those of Whelton et al., (2016) who conducted a similar
study in Cork University Hospital (CUH) and observed a VRE prevalence of 19.1% (67 out of 350
specimens) (95% CI: 14.1%-24.1%). Furthermore, of the 18 South Infirmary Victoria University
Hospital (SIVUH) samples analysed in our study, 3 were found to be VRE positive, with 2 of these

identified as first-time infections. Thus, in conjunction with the findings of Whelton et al. (2016), our
findings indicate that VRE carriage likely extends to a number of hospitals within the Cork region.
There was considerable variation in patient location at the time of VRE isolation, with isolates obtained
from patients in 7 different wards within the hospital, namely: the female medical ward, the general
inpatient ward, the geriatric ward, the ICU, the male medical ward, the male surgical ward, and the
semi-private ward (Table 1). The highest number of positive samples were identified in the ICU and
male surgical ward, which recorded 10 VRE isolates each. In both of these sample cohorts, 6 of the 10
(60%) positive samples were from patients with no history of VRE colonisation (i.e. first-time
infections). Five positive samples were obtained from the general inpatient ward, of which 4 (80%)
were first-time infections. Cumulatively, these findings indicate that patients in these wards are at an
increased likelihood of VRE colonisation, and that VRE carriage is dispersed throughout the hospital
as opposed to being confined to a particular location. Indeed, this observation is in line with Weterings
et al., (2021) who describe a VREfm outbreak in the Admiraal De Ruyter Hospital (The Netherlands)
that affected all but three wards. The high number of VRE isolates identified in the ICU is particularly
concerning given that VRE carriage is invariably associated with medical complications in vulnerable
patients (Se et al., 2009). However, this is not altogether surprising given that ICUs are at the epicentre
of several VRE outbreaks described in the literature (Hughes et al., 2019; Marom et al., 2020; Peta et
al., 2006), and while our study does not describe a full-scale VRE outbreak, a similar paradigm appears
to have emerged within the MUH.
Variation also existed in terms of the sample types from which VRE isolates were identified. The
majority of VRE isolates (16/34 or 47.1%) (95% CI: 30.3%-63.8%) were recovered from rectal swabs,
with wound swabs and urine samples accounting for four positive samples each (8/34 or 23.5%) (95%
CI: 9.3%-37.8%). Vaginal swabs and drain fluid samples accounted for two VRE isolates each, with
the remaining six VRE isolates being isolated from six different sample types (abscess swab, blood
culture, epigastric fluid, groin swab, penile swab, and stoma swab). The variety of positive sample types
re-emphasises the ubiquitous nature of the pathogen, and upon comparison of our data with Ulrich et
al., (2017), some differences can be noted: most importantly, the prevalence of VRE in blood cultures,
which in their systematic review accounted for 30.1% (141/468) of isolates – a ten-fold increase on the
2.9% (1/34) observed in our study. In addition to the marked difference in sample size, such discordance
may be explained by the variation in patient profiles and while our study involved the general patient
population, their review was confined solely to studies involving haematology/oncology patients. Thus,
it may be that these patients, often regarded as the most immunocompromised in the hospital setting
(Ruhnke et al., 2014), are at an inherently higher risk of VRE bloodstream infection (BSI) than the
general patient population – an observation that certainly warrants further investigation.

Table 1: VRE prevalence data obtained from clinical samples received in the Mercy University Hospital.
No. of VRE
isolated
0

No. of first-time VRE
infections
0

Prevalence (%)†

A&E

No. of samples
analysed
3

CCU

2

0

0

0

Female medical ward

3

1

1

33.3

General inpatient ward

7 (6)

5

4

66.7

Geriatric ward

2

1

1

50.0

ICU

37 (33)

10

6

18.2

Male medical ward

1

1

1

100

Male surgical ward

13 (9)

10

6

66.7

OPD

2

0

0

0

Other*

3

0

0

0

Paediatric ward

1

0

0

0

Semi-private ward

4 (1)

3

0

0

SIVUH

18 (17)

3

2

11.8

Urology ward

2

0

0

0

Total

98 (85)

34

21

24.7

Patient location

0

Where applicable, numbers in parentheses following the no. of samples analysed indicates the no. of samples analysed
excluding duplicate positives.
Note: A&E = Accident and Emergency; CCU = Coronary Care Unit; ICU = Intensive Care Unit; OPD = Outpatient
Department; SIVUH = South Infirmary Victoria University Hospital
† where prevalence (%) is the no. of first time VRE infections expressed in terms of the no. of samples analysed (excluding
𝑛𝑜.𝑜𝑓 𝑓𝑖𝑟𝑠𝑡 𝑡𝑖𝑚𝑒 𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛𝑠
100
duplicate positives (e.d.p.)) i.e. prevalence (%) =
x
𝑛𝑜.𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑎𝑛𝑎𝑙𝑦𝑠𝑒𝑑 (𝑒.𝑑.𝑝.)

1

* includes samples from Mercy Private Corridor, Hollyhill Medical Centre, and Shandon Medical Centre.

Environmental analysis
Owing to the high number of VRE isolated from patients in the male surgical ward, environmental
swabbing of the ward’s primary observation room was conducted in order to investigate the presence
of an environmental reservoir (Table 2). Three areas of the observation room were swabbed, resulting
in a total of 30 swabs submitted for analysis. The front desk area, from which 12 swabs were obtained,
was found to harbour VRE contamination in one site, namely the keyboard. Seven environmental swabs
were taken from the toilet area, with none of these showing evidence of VRE contamination. Of the 11
sites swabbed in the patient bedding area, two were positive for VRE, namely the electricity bar and
bedside desk of bedding area 2. In total, three of the 30 (10%) environmental swabs analysed in this
study were VRE contaminated. These findings are strongly suggestive of an active environmental VRE
reservoir within the primary observation room of the male surgical ward.
In contrast to the sparse VRE growth observed upon primary culture of the keyboard and electricity bar
swabs (1 CFU each), a near-confluent lawn of VRE growth was demonstrated upon primary culture of
the bedside desk swab (CFU = too numerous to count (TNTC)) (Table 2). Although the CFU method
may not be as accurate as a microscopic cell count, for example, it does allow for an estimate of
microbial abundance in an environmental sample (Andrés Christen & Parker, 2020; Cundell, 2015). In
this regard, it can be assumed that of the three positive environmental swabs, the bedside desk of

bedding area 2 carried the highest VRE burden. The significance of this observation is underpinned by
the fact that at the time of sample collection, this patient bedding area was vacant and presumably
awaiting the admission of a new patient, who, given the high environmental VRE load, would have
been at an increased likelihood of becoming colonised by the pathogen. Coupling this with the
identification of VRE isolates on the electricity bar, it is evident that the cleaning protocol utilised
following the discharge of the previous patient failed to eradicate residual VRE. Indeed, it is plausible
to hypothesise that this VRE reservoir existed for a considerable period of time and may have been a
source of infection prior to this study. As such, our results do not represent a novel find and VRE
contamination of these sites is to be expected when prevalence rates among patients are high.
The identification of VRE isolates on the keyboard is noteworthy given the frequency of its use by
hospital staff. Indeed, keyboard contamination is somewhat unsurprising as Schultz et al.(2003) report
that of the 100 keyboards tested in their hospital-wide study, 95 (95%) were positive for
microorganisms. Moreover, while most of these isolates were commensal-skin flora, four of the isolates
were enterococci, of which one was vancomycin-resistant. Similar rates of keyboard contamination
have also been reported by Nazeri et al., (2019), with microbes being identified on more than two-thirds
(76%) of the keyboards and electronic devices analysed in their cross-sectional study. Thus, it is clear
that keyboards represent a potential source of nosocomial infection in many hospitals and our findings
suggest the MUH cannot be considered an exception. Furthermore, while the keyboard analysed in our
study is confined to the primary observation room, the frequency of its use by doctors and nurses,
estimated to be 8.6 times/hour in one study, could facilitate VRE dissemination to distant areas within
the hospital (Hong et al., 2012).
The absence of VRE contaminants in the toilet area was largely unexpected, particularly given that the
toilet within the observation room is a communal facility; at any one time up to 5 patients may share its
use. In other studies, VRE isolates have been identified in hospital toilets, with Ulrich et al., (2017)
stressing that a special emphasis need be placed on toilets with respect to environmental VRE
disinfection. Thus, our findings may indicate that the shared toilet facility within the observation room
is, unlike other areas of the room, adequately cleaned as to prevent VRE persistence.

Table 2: Environmental sampling data obtained from the primary observation room of the male surgical
ward.
Site of swab
Door handles

VRE present (Y/N)

Degree of VRE growth in primary culture†

Front desk area
N

Telephone

N

Keyboard

Y

Chair armrest

N

Computer mouse

N

Bloodtrack devices

N

Light switches

N

Sink taps

N

Soap dispensers

N

Drawer handles

N

Monkey bar (4)

N

Remote control

N

+
-

Toilet area
Sink taps

N

Door handles

N

Toilet handle

N

Soap dispensers

N

Support rail

N

Toilet bowl surface

N

Paper towel holder

N

-

Patient bedding area
Chair armrest (1)

N

Table at end of bed (1)

N

Walking frame (1)

N

Windowsill

N

IV fluid holder (1)

N

Blood pressure monitor (1)

N

Electricity bar (2)

Y

Bed front railings (1)

N

Bed back railings (1)

N

Bedside desk (1)

N

Bedside desk (2)

Y

+
++++

Where applicable, numbers in parentheses following a swabbing site indicate which patient bedding area the swab was taken
from.
† where ‘-‘ = no growth; ‘+’ = 1-100 CFU; ‘++’ = 101-200 CFU; ‘+++’ = 201-300 CFU; ‘++++’ = too numerous to count
(TNTC) (>300 CFU)

Antimicrobial susceptibility testing
For all first-time VRE infections and positive environmental specimens, identification testing was
performed to provide a species-level resolution of the isolated enterococci. Antimicrobial susceptibility
testing (AST) was also conducted in order to elucidate the patterns of antimicrobial resistance present
within the VRE population (Table 3). In addition to the 24 VRE, one vancomycin-sensitive strain
(subsequently found to be linezolid-resistant), isolated from a wound swab of an ICU patient, was also
subject to identification and AST testing. All 24 presumptive positive VRE identified by culture (21
clinical and 3 environmental) were confirmed to be vancomycin-resistant by AST testing, with
minimum inhibitory concentration (MIC) values of >16g/mL reported for all isolates. Furthermore, in
agreement with Whelton et al. (2016), all isolates (n=24 VRE and n=1 VSE) investigated in our study
were identified as E. faecium (with VITEK identification probabilities ranging from 86%-98%),
implicating this species as the predominant nosocomial strain. As regards the mechanisms of
vancomycin-resistance, all isolates demonstrated the vanA genotype. Although confirmatory
polymerase-chain reaction (PCR) testing of van genotypes was not performed in our study, Abele-Horn
et al., (2006) report that 98.5% (65/66) of PCR-confirmed E. faecium vanA strains are correctly
characterised by the VITEK 2 system. Thus, it can be assumed that the majority, if not all, of the tested
VRE isolates were accurately characterised as vanA. In line with this, a key characteristic of vanA
subtypes, high-level teicoplanin resistance (MIC >16g/ml), was observed in all VRE isolates (Qu et
al., 2009).
Consistent with the findings of Engin et al. (2013) and Whelton et al. (2016), ampicillin-resistance was
observed in all isolates (MIC >16 g/mL), indicating the widespread prevalence of an ampicillinresistant VRE phenotype in the patient population. As regards antimicrobial synergism, the synergy
between a cell wall active agent (e.g. ampicillin) and an aminoglycoside (e.g. streptomycin) is best
predicted by screening for high level resistance to the aminoglycoside (Torres et al., 1995). As such,
the susceptibility of isolates to gentamicin, kanamycin, and streptomycin was investigated, with results
showing considerable variation between the three agents. With respect to gentamicin, all but two
isolates were shown to exhibit high-level resistance to the antibiotic. Interestingly, one of the susceptible
isolates was recovered from a drain fluid sample of a patient located in the male surgical ward and
further analysis revealed the entire AST profile of this isolate to be an exact replicate of that obtained
from both the keyboard and electricity bar (n=2) isolates however, more sophisticated methods, such as
the gold standard pulsed-field gel electrophoresis (PFGE) (Salipante et al., 2015), would be required to
conclusively determine the relatedness of these three strains.. Kanamycin resistance was observed in all
but one VRE isolate, indicating that synergistic combinations which incorporate kanamycin as an
aminoglycoside no longer represent an option for VRE treatment in the MUH. In contrast, susceptibility
to streptomycin varied among isolates, with 37.5% (9/24) observed to be resistant, and 62.5% (15/24)
remaining susceptible. Hence, of the three aminoglycosides investigated in this study, streptomycin
offers the greatest potential as a therapeutic against VRE, and may still be considered for treatment of
VRE infection against which other treatments have been exhausted.
Linezolid has been approved by the FDA for treatment of VREfm infections which are unresponsive to
first/second-line antimicrobial therapy (Hashemian et al., 2018). Commonly referred to as a ‘last-resort
antibiotic’, the use of linezolid is typically reserved for cases of severe infection whereby the causative
agent is multi-drug resistant (Sadowy, 2018). Given this status, it is concerning that one of the
enterococci identified in our study was linezolid-resistant. An MIC value of >4 g/mL was reported,
with the specimen subsequently being referred to a specialist centre (National MRSA Reference
Laboratory (NMRSARL)) for confirmatory MIC testing and PCR analysis. MIC testing conducted in
the NMRSARL revealed an MIC value of 8 g/mL (via broth dilution), and PCR analysis did not detect
the presence of the transferrable resistance genes cfr, optrA, and poxtA. These resistance determinants,
which are often nested within plasmid-borne mobile genetic elements (MGEs), are easily transferred
between bacteria and have the potential to mediate the widespread dissemination of linezolid-resistance
(Bender et al., 2019). The failure to detect these genes via PCR indicates that linezolid-resistance in
this isolate is governed by an alternative mechanism: most likely a mutation in bacterial ribosomes
and/or associated ribosomal proteins (Ruiz-Ripa et al., 2021). Given the non-transferable nature of these

mutations, it is unlikely that the isolate represents a real threat in terms of resistance dissemination.
Furthermore, while a clear linezolid-resistant phenotype was identified, the isolate was susceptible to
vancomycin, demonstrating an MIC value of <0.5g/mL. Nonetheless, the identification of this isolate
highlights the need for strict antimicrobial stewardship to prevent a vancomycin-resistant linezolidresistant phenotype emerging in the patient.
Tigecycline and quinupristin-dalfopristin were the only two antibiotics against which all of the isolated
VRE were susceptible. While these data are encouraging, it is important to note that the high rate of
quinupristin-dalfopristin susceptibility is likely a reflection of the sole isolation of E. faecium species
in our study. More precisely, although the rates of resistance to quinupristin-dalfopristin are low among
strains of VREfm, the converse is true for vancomycin-resistant E. faecalis, with only 3.2% of isolates
remaining susceptible according to one study (in contrast to 90.6% of VREfm) (Eliopoulos, 2003). Thus,
while quinupristin-dalfopristin therapy may be indicated for most VRE infections arising within the
MUH, this may not be the case with respect to infections in patients travelling from areas such as
Northern and Eastern Europe where vancomycin-resistant E. faecalis is more prominent (Ayobami et
al., 2020).
Table 3: VITEK 2 Compact antimicrobial susceptibility testing (AST-P662 card) on presumptive positive
vancomycin-resistant enterococci recovered from first-time infections and environmental samples.
Antimicrobial

No. of isolates
tested*

No. of isolates
susceptible

No. of isolates
resistant

Likely to be
effective †

Ampicillin (AMP)

24

0

24

❌

Gentamicin (GEN)

24

4

20

❌

Kanamycin (KAN)

24

1

23

❌

Linezolid (LZD)
QuinupristinDalfopristin (Q/D)
Streptomycin (STM)

24

24

0

✅

24

24

0

✅

24

15

9

✅

Teicoplanin (TEI)

24

0

24

❌

Tigecycline (TIG)

24

24

0

✅

Vancomycin (VAN)

24

0

24

❌

† where the majority of isolates were found to be susceptible an antibiotic was considered ‘likely to be effective’
* the linezolid-resistant isolate also underwent AST analysis but was vancomycin-sensitive and so was excluded from the
above-shown data. This isolate had the following resistotype: AMP-GEN-KAN-LZD.

Infection prevention and control
In the context of pathogen containment, an emergency meeting was conducted in April 2021 in order
to address the findings of this study. Many of the topics discussed are in line with the guidelines set out
by the Hospital Infection Controls Practice Advisory Committee (HICPAC) as regards preventing the
spread of vancomycin-resistance in the hospital-setting (CDC, 1995). These guidelines, which require
a coordinated interdisciplinary approach, are comprised of four core elements: a) the prudent use of
vancomycin by clinicians, b) education of all hospital staff regarding the impact of VRE, c) early
detection and reporting of VRE by laboratory staff, and d) the prompt implementation of infection
control measures to prevent person-person VRE transmission (CDC, 1995).
Regarding vancomycin usage, it has been estimated that in an estimated 34-67% of cases, its use could
be considered inappropriate, with methicillin-resistant Staphylococcus aureus (MRSA) being cited as a
contributory factor in many hospitals (i.e. use of vancomycin to treat MRSA often favours the
emergence of VRE) (Junior et al., 2007). While neither the prevalence of MRSA nor the frequency of

vancomycin use were investigated in our study, our findings highlight the need for prescribing clinicians
to adopt a cautious approach moving forward.
Education of hospital staff, in particular nurses and other ward-level personnel, on the significance of
VRE was an obvious requirement given the high number of first-time infections arising in many wards.
The importance of proper hygiene was relayed to the relevant staff, with an emphasis on handwashing
technique, use of personal protective equipment (PPE), and surface disinfection (Mutters et al., 2013).
As regards the environmental reservoir, the seriousness of the issue was highlighted and the use of a
plastic keyboard cover in tandem with frequent disinfection was implemented (Hong et al., 2012).
Given that the microbiology laboratory serves as the first-line of defense against VRE spread in the
hospital setting (CDC, 1995), laboratory staff play a central role in breaking the chains of pathogen
transmission. With a view to ensuring patient-patient and patient-staff VRE transmission is minimised
within the hospital, the need for prompt identification and reporting of VRE-positive patients was
reiterated to microbiology staff. In addition, the continued monitoring of VRE prevalence was
recommended to allow for the early-identification of VRE clusters emerging at the ward-level.
Limitations
This study had a number of limitations. Firstly, although the study was conducted over a considerable
time period, the sample size (n=98) was relatively small. Secondly, owing to a lack of resources and
financial constraints, molecular typing of VRE isolates was not performed in this study. Although an
attempt was made to determine the relatedness of strains by comparison of AST profiles, this cannot be
considered an adequate substitution for molecular methods such as PFGE and multilocus sequence
typing (MLST).
Using PFGE, Ryan et al. (2015) determined the clonal relatedness of VRE strains obtained from patients
within St. Vincent's University Hospital (SVUH), allowing them to decipher the epidemiological links
between many of the isolates and establish the likely starting points for several clusters of infection.
Thus, it is clear that molecular typing adds an extra dimension to prevalence data and should be
incorporated into future studies. Finally, given that only three areas in the primary observation room of
the male surgical ward were sampled, it is likely that the VRE burden within this area, if not the entire
ward, is greater than our results imply. In addition, environmental sampling of other wards from which
high numbers of first-time infections were reported, such as the general inpatient ward and the ICU, is
needed to determine if VRE reservoirs exist in these areas.

CONCLUSION
In summary, the findings described herein reveal high rates of VRE carriage among patients within the
MUH, while also pointing towards the presence of an active environmental reservoir in the male
surgical ward. In line with other Irish studies (Morris-Downes et al., 2010; Ryan et al., 2015; Whelton
et al., 2016), vanA VREfm appears to be the predominant nosocomial strain, with linezolid-resistance
still a cause for concern. It is hoped that this study highlights the ongoing threat posed by VRE in the
hospital setting and may, at least in part, help to explain why Ireland continues to surpass its neighbours
in terms of VRE prevalence.

ACKNOWLEDGEMENTS
I would like to thank all the staff in the Clinical Microbiology department of the MUH for their
assistance during this study. In particular, I would like to thank Siobhan Fitzgibbon (Senior Medical
Scientist), Dr. Deirdre O'Brien (Consultant Microbiologist), Sinead Fahy (Medical Scientist), and

Joanne Crowley (Infection Control Specialist) for their support throughout. I would also like to thank
Shane Whelan and Caoimhe Lynch for their guidance, and the staff in the NMRSARL for providing
confirmatory testing of the linezolid-resistant isolate. Finally, I wish to acknowledge Dr. Brigid Lucey
for encouraging me to publish this work.

Corresponding author: Dylan Casey (dylan.casey1@mycit.ie)

REFERENCES
Abele-Horn, M., Hommers, L., Trabold, R., & Frosch, M. (2006). Validation of VITEK 2 version 4.01 software
for detection, identification, and classification of glycopeptide-resistant enterococci. Journal of Clinical
Microbiology, 44(1), 71–76. https://doi.org/10.1128/JCM.44.1.71-76.2006
Alqarni, A., Kantor, E., Grall, N., Tanaka, S., Zappella, N., Godement, M., Ribeiro-Parenti, L., Tran-Dinh, A., &
Montravers, P. (2018). Clinical characteristics and prognosis of bacteraemia during postoperative intraabdominal infections. Critical Care, 22(1), 175. https://doi.org/10.1186/s13054-018-2099-5
Andrés Christen, J., & Parker, A. E. (2020). Systematic statistical analysis of microbial data from dilution series.
Austin, D. J., Bonten, M. J. M., Weinstein, R. A., Slaughter, S., & Anderson, R. M. (1999). Vancomycin-resistant
enterococci in intensive-care hospital settings: Transmission dynamics, persistence, and the impact of
infection control programs. Proceedings of the National Academy of Sciences of the United States of
America, 96(12), 6908–6913. https://doi.org/10.1073/pnas.96.12.6908
Ayobami, O., Willrich, N., Reuss, A., Eckmanns, T., & Markwart, R. (2020). The ongoing challenge of
vancomycin-resistant Enterococcus faecium and Enterococcus faecalis in Europe: an epidemiological
analysis of bloodstream infections. Emerging Microbes & Infections, 9(1), 1180–1193.
https://doi.org/10.1080/22221751.2020.1769500
Bender, J. K., Fleige, C., Klare, I., & Werner, G. (2019). Development of a multiplex-PCR to simultaneously
detect acquired linezolid resistance genes cfr, optrA and poxtA in enterococci of clinical origin. Journal of
Microbiological Methods, 160, 101–103. https://doi.org/10.1016/j.mimet.2019.03.025
Byappanahalli, M. N., Nevers, M. B., Korajkic, A., Staley, Z. R., & Harwood, V. J. (2012). Enterococci in the
Environment.
Microbiology
and
Molecular
Biology
Reviews,
76(4),
685–706.
https://doi.org/10.1128/mmbr.00023-12
CDC. (1995). Recommendations for preventing the spread of vancomycin resistance: Recommendations of the
Hospital Infection Control Practices Advisory Committee (HICPAC). AJIC: American Journal of Infection
Control, 23(2), 87–94. https://doi.org/10.1016/0196-6553(95)90104-3
Cundell, T. (2015). The limitations of the colony-forming unit in microbiology. European Pharmaceutical
Review, 20(6), 11–13. https://www.europeanpharmaceuticalreview.com/article/37416/the-limitations-ofthe-colony-forming-unit-in-microbiology/
Eliopoulos, G. M. (2003). Quinupristin-dalfopristin and linezolid: Evidence and opinion. In Clinical Infectious
Diseases (Vol. 36, Issue 4, pp. 473–481). Oxford Academic. https://doi.org/10.1086/367662
Engin, D. Ö., Baldır, G., Öztürk Engin, D., Küçükercan, M., İnan, A., Akçay, S., Özyürek, S., & Aksaray, S.
(2013). High-level resistance to aminoglycoside, vancomycin, and linezolid in enterococci strains. Journal
of Microbiology and Infectious Diseases, 3(3), 100–103. https://doi.org/10.5799/ahinjs.02.2013.03.0090
García-Solache, M., & Rice, L. B. (2019). The enterococcus: A model of adaptability to its environment. In
Clinical Microbiology Reviews (Vol. 32, Issue 2). American Society for Microbiology.
https://doi.org/10.1128/CMR.00058-18

Griffith, R. S. (1984). Vancomycin use - An historical review. Journal of Antimicrobial Chemotherapy,
14(SUPPL. D), 1–5. https://doi.org/10.1093/jac/14.suppl_d.1
Hashemian, S. M. R., Farhadi, T., & Ganjparvar, M. (2018). Linezolid: A review of its properties, function, and
use in critical care. In Drug Design, Development and Therapy (Vol. 12, pp. 1759–1767). Dove Medical
Press Ltd. https://doi.org/10.2147/DDDT.S164515
Hazan, R., Que, Y.-A., Maura, D., & Rahme, L. G. (2012). A method for high throughput determination of viable
bacteria cell counts in 96-well plates. BMC Microbiology 2012 12:1, 12(1), 1–7.
https://doi.org/10.1186/1471-2180-12-259
Hong, D., Sang, P. O., Dae Young, H., Kyeong Ryong, L., Kwang Je, B., Seung Baik, H., & Kong, H. (2012).
Bacterial contamination of computer and hand hygiene compliance in the emergency department. In Hong
Kong Journal of Emergency Medicine j. emerg. med (Vol. 19, Issue 6).
Hughes, A., Ballard, S., Sullivan, S., & Marshall, C. (2019). An outbreak of vanA vancomycin-resistant
Enterococcus faecium in a hospital with endemic vanB VRE. Infection, Disease and Health, 24(2), 82–91.
https://doi.org/10.1016/j.idh.2018.12.002
Iaria, C., Stassi, G., Costa, G. B., Di Leo, R., Toscano, A., & Cascio, A. (2005). Enterococcal meningitis caused
by Enterococcus casseliflavus. First case report. BMC Infectious Diseases 2005 5:1, 5(1), 1–3.
https://doi.org/10.1186/1471-2334-5-3
Jung, E., Byun, S., Lee, H., Moon, S. Y., & Lee, H. (2014). Vancomycin-resistant Enterococcus colonization in
the intensive care unit: Clinical outcomes and attributable costs of hospitalization. American Journal of
Infection Control, 42(10), 1062–1066. https://doi.org/10.1016/j.ajic.2014.06.024
Junior, M. S., Correa, L., Marra, A. R., Camargo, L. F. A., & Pereira, C. A. P. (2007). Analysis of vancomycin
use and associated risk factors in a university teaching hospital: A prospective cohort study. BMC Infectious
Diseases, 7, 88. https://doi.org/10.1186/1471-2334-7-88
Kristich, C. J., Rice, L. B., & Arias, C. A. (2014). Enterococcal Infection—Treatment and Antibiotic Resistance.
Enterococci: From Commensals to Leading Causes of Drug Resistant Infection.
https://www.ncbi.nlm.nih.gov/books/NBK190420/
Leibovici, L. (1995). Bacteraemia in the Very Old: Features and Treatment. In Drugs & Aging (Vol. 6, Issue 6,
pp. 456–464). Drugs Aging. https://doi.org/10.2165/00002512-199506060-00005
Marom, R., Mandel, D., Haham, A., Berger, I., Ovental, A., Raskind, C., Grisaru-Soen, G., Adler, A., Lellouche,
J., Schwartz, D., Carmeli, Y., & Schechner, V. (2020). A silent outbreak of vancomycin-resistant
Enterococcus faecium in a neonatal intensive care unit. Antimicrobial Resistance & Infection Control 2020
9:1, 9(1), 1–6. https://doi.org/10.1186/S13756-020-00755-0
Mcdermott, H., Skally, M., O’rourke, J., Humphreys, H., & Fitzgerald-Hughes, D. (2018). Vancomycin-Resistant
Enterococci (VRE) in the intensive care unit in a nonoutbreak setting: Identification of potential reservoirs
and epidemiological associations between patient and environmental VRE. In Infection Control and
Hospital Epidemiology (Vol. 39, Issue 1, pp. 40–45). Cambridge University Press.
https://doi.org/10.1017/ice.2017.248
Mendes, R. E., Castanheira, M., Farrell, D. J., Flamm, R. K., Sader, H. S., & Jones, R. N. (2016). Longitudinal
(2001–14) analysis of enterococci and VRE causing invasive infections in European and US hospitals,
including a contemporary (2010–13) analysis of oritavancin in vitro potency. Journal of Antimicrobial
Chemotherapy, 71(12), 3453–3458. https://doi.org/10.1093/jac/dkw319
Morris-Downes, M., Smyth, E. G., Moore, J., Thomas, T., Fitzpatrick, F., Walsh, J., Caffrey, V., Morris, A.,
Foley, S., & Humphreys, H. (2010). Surveillance and endemic vancomycin-resistant enterococci: Some
success in control is possible. Journal of Hospital Infection, 75(3), 228–233.
https://doi.org/10.1016/J.JHIN.2010.01.004
Mutters, N. T., Mersch-Sundermann, V., Mutters, R., Brandt, C., Schneider-Brachert, W., & Frank, U. (2013).

Control of the spread of vancomycin-resistant enterococci in hospitals: Epidemiology and clinical relevance.
Deutsches Arzteblatt International, 110(43), 725. https://doi.org/10.3238/arztebl.2013.0725
Nazeri, M., Salmani Arani, J., Ziloochi, N., Delkhah, H., Hesami Arani, M., Asgari, E., & Hosseini, M. (2019).
Microbial contamination of keyboards and electronic equipment of ICU (Intensive Care Units) in Kashan
University of medical sciences and health service hospitals. MethodsX, 6, 666–671.
https://doi.org/10.1016/j.mex.2019.03.022
Neely, A. N., & Maley, M. P. (2000). Survival of enterococci and staphylococci on hospital fabrics and plastic.
Journal of Clinical Microbiology, 38(2), 724–726. https://doi.org/10.1128/jcm.38.2.724-726.2000
Peta, M., Carretto, E., Barbarini, D., Zamperoni, A., Carnevale, L., Perversi, L., Pagani, M., Bonora, M. G.,
Fontana, R., Marone, P., & Langer, M. (2006). Outbreak of vancomycin-resistant Enterococcus spp. in an
Italian general intensive care unit. Clinical Microbiology and Infection, 12(2), 163–169.
https://doi.org/10.1111/J.1469-0691.2005.01331.X
Qu, T. T., Zhang, J. L., Zhou, Z. H., Wei, Z. Q., Yu, Y. S., Chen, Y. G., & Li, L. J. (2009). Heteroresistance to
teicoplanin in Enterococcus faecium harboring the vanA gene. In Journal of Clinical Microbiology (Vol.
47,
Issue
12,
pp.
4194–4196).
American
Society
for
Microbiology
Journals.
https://doi.org/10.1128/JCM.01802-09
Rajkumari, N., Mathur, P., & Misra, M. C. (2014). Soft tissue and wound infections due to Enterococcus spp.
among hospitalized trauma patients in a developing country. Journal of Global Infectious Diseases, 6(4),
189–193. https://doi.org/10.4103/0974-777X.145253
Rawlinson, S., Ciric, L., & Cloutman-Green, E. (2019). How to carry out microbiological sampling of healthcare
environment surfaces? A review of current evidence. In Journal of Hospital Infection (Vol. 103, Issue 4,
pp. 363–374). W.B. Saunders Ltd. https://doi.org/10.1016/j.jhin.2019.07.015
Rosselli Del Turco, E., Bartoletti, M., Dahl, A., Cervera, C., & Pericàs, J. M. (2020). How do I manage a patient
with
enterococcal
bacteraemia?
Clinical
Microbiology
and
Infection,
0(0).
https://doi.org/10.1016/j.cmi.2020.10.029
Ruhnke, M., Arnold, R., & Gastmeier, P. (2014). Infection control issues in patients with haematological
malignancies in the era of multidrug-resistant bacteria. The Lancet Oncology, 15(13), e606–e619.
https://doi.org/10.1016/S1470-2045(14)70344-4
Ruiz-Ripa, L., Feßler, A. T., Hanke, D., Eichhorn, I., Azcona-Gutiérrez, J. M., Alonso, C. A., Pérez-Moreno, M.
O., Aspiroz, C., Bellés, A., Schwarz, S., & Torres, C. (2021). Mechanisms of Linezolid Resistance among
Clinical Staphylococcus spp. In Spain: Spread of Methicillin-and Linezolid-Resistant S. epidermidis ST2.
Microbial Drug Resistance, 27(2), 145–153. https://doi.org/10.1089/mdr.2020.0122
Ryan, L., O’Mahony, E., Wrenn, C., FitzGerald, S., Fox, U., Boyle, B., Schaffer, K., Werner, G., & Klare, I.
(2015). Epidemiology and molecular typing of VRE bloodstream isolates in an Irish tertiary care hospital.
Journal of Antimicrobial Chemotherapy, 70(10), 2718–2724. https://doi.org/10.1093/JAC/DKV185
Sadowy, E. (2018). Linezolid resistance genes and genetic elements enhancing their dissemination in enterococci
and
streptococci.
In
Plasmid
(Vol.
99,
pp.
89–98).
Academic
Press
Inc.
https://doi.org/10.1016/j.plasmid.2018.09.011
Salipante, S. J., SenGupta, D. J., Cummings, L. A., Land, T. A., Hoogestraat, D. R., & Cookson, B. T. (2015).
Application of whole-genome sequencing for bacterial strain typing in molecular epidemiology. Journal of
Clinical Microbiology, 53(4), 1072–1079. https://doi.org/10.1128/JCM.03385-14
Schultz, M., Gill, J., Zubairi, S., Huber, R., & Gordin, F. (2003). Bacterial Contamination of Computer Keyboards
in a Teaching Hospital. Infection Control & Hospital Epidemiology, 24(4), 302–303.
https://doi.org/10.1086/502200
Se, Y. B., Chun, H. J., Yi, H. J., Kim, D. W., Ko, Y., & Oh, S. J. (2009). Incidence and risk factors of infection
caused by vancomycin-resistant enterococcus colonization in neurosurgical intensive care unit patients.

Journal of Korean Neurosurgical Society, 46(2), 123–129. https://doi.org/10.3340/jkns.2009.46.2.123
Selleck, E. M., Tyne, D. Van, & Gilmore, M. S. (2019). Pathogenicity of Enterococci. Microbiology Spectrum,
7(4). https://doi.org/10.1128/MICROBIOLSPEC.GPP3-0053-2018
Torres, C., Tenorio, C., Lantero, M., Zarazaga, M., & Baquero, F. (1995). Detection of aminoglycoside-penicillin
synergy against Enterococcus faecium using high-content aminoglycoside disks. European Journal of
Clinical Microbiology & Infectious Diseases, 14(10), 878–882. https://doi.org/10.1007/BF01691494
Ulrich, N., Vonberg, R. P., & Gastmeier, P. (2017). Outbreaks caused by vancomycin-resistant Enterococcus
faecium in hematology and oncology departments: A systematic review. Heliyon, 3(12).
https://doi.org/10.1016/j.heliyon.2017.e00473
Uttley, A. H. C., Collins, C. H., Naidoo, J., & George, R. C. (1988). VANCOMYCIN-RESISTANT
ENTEROCOCCI. In The Lancet (Vol. 331, Issues 8575–8576, pp. 57–58). https://doi.org/10.1016/S01406736(88)91037-9
Weterings, V., van Oosten, A., Nieuwkoop, E., Nelson, J., Voss, A., Wintermans, B., van Lieshout, J., Kluytmans,
J., & Veenemans, J. (2021). Management of a hospital-wide vancomycin-resistant Enterococcus faecium
outbreak in a Dutch general hospital, 2014–2017: successful control using a restrictive screening strategy.
Antimicrobial Resistance and Infection Control, 10(1). https://doi.org/10.1186/s13756-021-00906-x
Whelton, E., Lynch, C., O’Reilly, B., Corcoran, G. D., Cryan, B., Keane, S. M., Sleator, R. D., & Lucey, B.
(2016). Vancomycin-resistant enterococci carriage in an acute Irish hospital. Journal of Hospital Infection,
93(2), 175–180. https://doi.org/10.1016/j.jhin.2016.03.005

